Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...

IF YOU ARE AN INVESTOR WHO LOST MONEY ON KYVERNA THERAPEUTICS ... and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously ...

EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...

On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite ...

Kyverna Therapeutics, Inc. (KYTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ ...

Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the Company’s research, clinical development, and medical ...

As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the ...

Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna ... announced it will present its 2025 strategic priorities and key milestones during a presentation that will be made by Chief ...